Several equities research analysts recently issued reports on HOLX shares. Zacks Investment Research upgraded Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price objective on the stock in a report on Tuesday, April 4th. Barclays PLC set a $50.00 price objective on Hologic and gave the company a “buy” rating in a report on Wednesday, April 5th. Stifel Nicolaus boosted their price objective on Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Canaccord Genuity reiterated a “buy” rating and issued a $53.00 price objective on shares of Hologic in a report on Tuesday, May 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $47.00 price objective on shares of Hologic in a report on Sunday, May 14th.
Hologic, Inc. (NASDAQ:HOLX) has been assigned an average recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $47.67.
Hologic (NASDAQ:HOLX) opened at 45.13 on Tuesday. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80. The stock has a market cap of $12.64 billion, a price-to-earnings ratio of 16.18 and a beta of 0.91. The stock’s 50 day moving average price is $45.10 and its 200 day moving average price is $42.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.04. The firm had revenue of $715.40 million for the quarter, compared to the consensus estimate of $685.24 million. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.47 EPS. On average, analysts forecast that Hologic will post $2.01 earnings per share for the current year.
In other Hologic news, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $43.99, for a total transaction of $393,182.62. Following the sale, the director now owns 23,810 shares in the company, valued at approximately $1,047,401.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 10,203 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $45.00, for a total value of $459,135.00. Following the sale, the director now owns 38,832 shares in the company, valued at approximately $1,747,440. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,139 shares of company stock worth $3,722,376. 0.79% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its position in Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock worth $58,032,000 after buying an additional 798,541 shares during the last quarter. Whalerock Point Partners LLC increased its position in Hologic by 57.4% in the fourth quarter. Whalerock Point Partners LLC now owns 37,850 shares of the medical equipment provider’s stock worth $1,519,000 after buying an additional 13,800 shares during the last quarter. Teachers Advisors LLC increased its position in Hologic by 28.8% in the fourth quarter. Teachers Advisors LLC now owns 643,547 shares of the medical equipment provider’s stock worth $25,819,000 after buying an additional 143,960 shares during the last quarter. Kentucky Retirement Systems acquired a new position in Hologic during the fourth quarter worth approximately $810,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Hologic during the fourth quarter worth approximately $361,000. Institutional investors own 94.09% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.